Endovia Health Sciences, Inc. (EDVA) · Oct 27, 2026 · Share issuance
$100M equity-line expansion — Maximum commitment increased from $35M to $135M
Endovia’s equity-line amendment raises potential funding capacity to $135 million, but draws remain optional, dilutive, and conditional.
Endovia is in the middle of a transition from a legacy beverage company into a cannabinoid health-sciences platform, including pharmaceutical and veterinary programs such as CannEpil. The filing materially increases potential financing capacity, not current liquidity. The amendment raises the maximum commitment under the existing purchase agreement from $35 million to $135 million, inclusive of prior sales. 〔0〕
| Item | Filing detail |
|---|---|
| Prior maximum commitment | $35 million (I. Incorporation of Exhibit A) |
| Revised maximum commitment | $135 million (I. Incorporation of Exhibit A) |
| Incremental capacity | $100 million (calculated from the filing’s two commitment limits) |
| Commitment period | Up to 36 months (Exhibit A — Term) |
| Fixed-purchase discount | 5% below the lower reference price, implying a 95% purchase price (Exhibit A — Fixed Purchases) |
| Maximum single fixed purchase | $500,000 (Exhibit A — Fixed Purchases) |
| Commitment fee note | 2% of the $100 million commitment, or $2 million (Exhibit A — Commitment Fee Note) |
The funding is a backstop, not a committed $100 million investment. Endovia controls whether and when to issue purchase notices and is not required to sell shares; the investor becomes obligated only after a valid notice and satisfaction of conditions including an effective resale registration statement, continued exchange listing, and applicable ownership or issuance caps. 〔1〕
The capital comes with substantial dilution risk and investor-friendly pricing. New shares are sold at 95% of specified market-price benchmarks, with fixed purchases capped at $500,000 each but aggregate daily fixed purchases potentially reaching $10 million; additional VWAP purchases can bring total same-day purchases to $2 million under the stated VWAP limits. The investor also receives a 2% commitment-fee note, equal to $2 million based on the stated $100 million commitment. These terms can provide runway for the CannEpil and broader platform buildout, but they make the financing dependent on issuing an increasing number of shares as the stock price falls.
The headline capacity overstates the certainty of the financing. Exhibit A says the term sheet’s provisions other than confidentiality are nonbinding and remain subject to due diligence, even though the addendum incorporates the new terms into the purchase agreement. 〔2〕 That conflict leaves the practical availability and enforceability of the full incremental capacity less clear than the $135 million headline suggests.
Bottom line: This strengthens Endovia’s potential access to capital during its cannabinoid-platform transition, but it is not cash in hand and carries meaningful dilution. The business gets financing optionality—not a fully committed $100 million funding package—so the event is genuinely two-sided versus the standing story.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!